Navigation Links
Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts

CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration), the only biopharmaceutical company focused exclusively on the development and commercialization of new treatment options for people with hemophilia, announced today the Company will relocate its corporate headquarters to Cambridge, MA from Laguna Niguel, CA.  The move is integral to Inspiration's plan to accommodate its anticipated future staffing and facility needs as the Company transitions to product commercialization.

Inspiration's new location at One Kendall Square is ideally located within the greater Boston area's technology and life sciences cluster.  The new address is:

Inspiration Biopharmaceuticals
One Kendall Square
Cambridge, MA 02139

John P. Butler, Chief Executive Officer of Inspiration, commented, "The Boston metro area has always been a center for growth and innovation in the biopharmaceutical industry.  As we move toward the launch of Inspiration's first products, including IB1001, our recombinant factor IX product for hemophilia B, it is the perfect location to establish our corporate office.  We expect the close proximity to some of the leading academic and research institutions will help attract top talent as we continue to build a world-class company focused on improving the life of individuals with hemophilia."

In October 2011, Inspiration named John P. Butler Chief Executive Officer.  Mr. Butler joined Inspiration from Cambridge-based Genzyme Corporation, where he most recently served as President of the company's rare genetic diseases business.

One Kendall Square is in the heart of Cambridge's life-sciences community.  Since its inception, this address has served as headquarters for many early-stage to mid-tier companies, including a number that have gone on to develop blockbuster drugs and employ thousands of workers in Greater Boston.  The office and research park is situated on nine acres.

About Inspiration Biopharmaceuticals
Inspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care to safe and effective recombinant therapies and advance innovation for people living with these conditions.  Inspiration has a broad portfolio of recombinant hemophilia products, which includes two products in late-stage clinical development and two preclinical programs.

Inspiration's lead product candidates are IB1001, an intravenous recombinant factor IX (FIX) product for the treatment and prevention of bleeding in individuals with hemophilia B, and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product for the treatment of individuals with congenital hemophilia A who have developed inhibitors against human FVIII and for individuals with acquired hemophilia.  Inspiration recently submitted its first marketing application for IB1001 in Europe, with a subsequent regulatory filing planned in the U.S.  Earlier-stage preclinical programs at Inspiration are focused on human recombinant factor VIIa (FVIIa), for individuals with either hemophilia A or hemophilia B who have developed inhibitors, and for individuals with factor VII deficiency; and human recombinant FVIII, to treat individuals with hemophilia A.

Inspiration's senior management team has broad experience and expertise in hemophilia product development, biologics manufacturing and the successful commercialization of products to treat both hemophilia as well as chronic orphan diseases.

In addition, in January 2010, Inspiration entered into a strategic partnership with the Ipsen Group (EURONEXT: IPN; ADR: IPSEY), leveraging the combined expertise and resources of the two companies, to develop a broad portfolio of hemophilia products.  As announced in late August 2011, Ipsen and Inspiration extended their partnership to create a hemophilia business unit structure that will act as the exclusive sales organization for all hemophilia products commercialized under the Inspiration brand in Europe.  For further information on Inspiration, please visit

 Contacts: MediaCompanyJustin JacksonGordon H. BusenbarkMichelle SzwarcbergSenior Vice President, Chief Financial OfficerBurns McClellanEmail: Tel: +1-212-213-0006




SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
2. Using magnetic toys as inspiration, researchers tease out structures of self-assembled clusters
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
6. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
7. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
11. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):